DAY ONE 3 APRIL

DC Plenary Day April 3

MORNING PLENARIES

Dr Justin R Ortiz
08:40

Immunization across the lifespan – What will it take? A WHO perspective

  • Building routine influenza immunization programs in low-resource settings
  • Vaccinations in adulthood: An important role in public health and in reducing morbidity and mortality rates
  • Why are adults often behind in many vaccinations?
Dr Carl Alving
09:05

Adjuvant technology and its impact on vaccine development

  • Analysis of the importance and role of innate immunity
  • Formulation of novel adjuvant combinations
Dr Derek O'Hagan
09:30

Designing and building the next generation of vaccine adjuvants

  • Discovery of adjuvants, their optimal delivery and how they advance into clinical evaluation and assessment of their performance
  • Creating robust and scalable formulations
  • Negotiating a path to potential approval
Dr Mathuram Santosham
09:55

What it takes to get a vaccine from research to near elimination of H influenza type b (Hib) diseases globally: Saving 7 million lives by 2020

  • How the pivotal PRP-OMP conjugate vaccine efficacy trial was designed and conducted, leading to the licensure of the vaccine (Pedvax Hib)
  • Challenges and triumphs – lessons learned that can be applied to today’s vaccine research and trials for global access
10:20

Networking coffee break

11:20

INTERACTIVE ROUNDTABLES

Choose two roundtable sessions back-to-back and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis – 40 min per roundtable

Best practices for a Successful CRO/Pharma partnership for Vaccine Clinical Studies

Title TBC

Clinical Development & trials: Conducting clinical trials in low resource settings

Developing more effective vaccines for emerging/re-emerging pandemic threats

Senior representative, ClinicalRM TBC

Discovering pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development

DNA, live vectors, adjuvanted vaccines. 30 years later, are they inter changeable or is there a specific use for each?

How can we actually apply big data and AI into smarter vaccine design?

How to measure and develop dual use vaccines?

Managing your cold chain – Lessons learned from the Ebola clinical trials

Pre-clinical safety considerations when working with live virus and LNP based vaccines

Dr Lisa Plitnick, Senior Principal Investigator, Pre-Clinical Vaccine Safety,, Merck

Unexpected drivers of performance; doses per vaccine vial

12:40

Networking Lunch & Poster Session

AFTERNOON PLENARIES

Dr Vasee Moorthy
3:10

Enabling guidance from the World Health Organization

-          WHO’s target product profiles for outbreak vaccine development

-          Data and sample sharing in emergencies and during the inter-emergency period

3:40

Networking coffee break

Panel discussion
4:10

Executive cancer panel: How will recent breakthroughs in immuno-oncology determine cancer vaccine and combinational treatments?

  • The significance of check point inhibitors, oncolytic viruses neoantigens, CAR T-cells and ACT on cancer immunotherapy progress
  • Supporting evidence from combinational studies
  • The role of cancer vaccines in the future of combinational approaches
Dr Bruce Gellin
4:55

The role of vaccines to combat antibiotic-resistant bacteria

  • Insights and recommendations from the national vaccine advisory committee and Chatham house
  • Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
Dr Gary Nabel
5:20

Trispecific abs and novel platforms to prevent HIV and other viral infections

Dr Gregory A. Poland
5:40

Chair’s closing remarks and close of congress day 1

5:50

Pre-Awards Networking Drinks Reception

6:50

Gala Dinner & 11th Annual ViE Awards Ceremony

last published: 22/Nov/17 13:35 GMT